Medical Management of Peripheral Arterial Disease (PAD)

1. Antithrombotic Therapy

Antiplatelet Agents

• Aspirin 75-325 mg/day - a COX-1 inhibitor, the most widely used agent
• Clopidogrel 75 mg/day - a P2Y12 receptor antagonist; in the CAPRIE trial, clopidogrel was superior to aspirin in symptomatic PAD patients (3.71% vs. 4.86% annual event rate). Clopidogrel is preferred in current smokers, as it has shown greater event reduction vs. aspirin in this group
• Ticagrelor 90 mg twice daily - In the EUCLID trial, ticagrelor showed similar benefit to clopidogrel monotherapy (HR 1.02); may have a role in poor clopidogrel metabolizers

Dual Antiplatelet Therapy (DAPT)

• DAPT (aspirin + P2Y12 antagonist) was NOT shown to reduce MACE more than aspirin alone in PAD in the CHARISMA trial, and increases bleeding risk
• Exception: In PAD patients with a prior MI, adding ticagrelor to low-dose aspirin reduced both MACE and major adverse limb events (MALE) in PEGASUS-TIMI 54
• DAPT is commonly used after peripheral endovascular interventions, though clear supporting trial data are limited

Low-Dose Oral Anticoagulation (Pathway Antithrombotic Strategy)

• Rivaroxaban 2.5 mg twice daily + aspirin is supported by two major trials:
  • COMPASS trial: In 6,391 PAD patients, this combination reduced MACE (5.1% vs. 6.9%, p=0.005) and MALE (1.5% vs. 2.6%, HR 0.57) vs. aspirin alone
  • VOYAGER-PAD trial: In 6,564 patients post-revascularization, rivaroxaban + aspirin reduced a composite of acute limb ischemia, major amputation, MI, stroke, and cardiovascular death (HR 0.85, p=0.009)
  • A meta-analysis of both trials confirmed superiority of the combination over aspirin alone for cardiovascular and limb events
• Major bleeding was increased with rivaroxaban, though fatal/critical organ bleeding was not significantly different
• Recommendation: Aspirin + low-dose rivaroxaban is reasonable in patients without elevated bleeding risk; full-dose anticoagulation is NOT routinely recommended as benefit does not outweigh bleeding risk

Vorapaxar

• A PAR-1 (thrombin receptor) antagonist approved for reducing thrombotic cardiovascular events in patients with a history of MI or PAD
• Contraindicated in patients with prior intracranial hemorrhage due to increased major bleeding risk

2. Lipid-Lowering Therapy

• Target: LDL < 70 mg/dL
• Agents: Rosuvastatin 40 mg/day or simvastatin 80 mg/day (though simvastatin 80 mg carries myopathy risk)
• Statins reduce mortality, MACE, MALE, and improve symptomatic outcomes. They also have pleiotropic effects: improved endothelial function, smooth muscle proliferation inhibition, plaque stabilization, and reduced platelet aggregation
• A VA population-based study of 155,647 patients showed high-intensity statin at PAD diagnosis significantly reduced limb loss and mortality

1. Add ezetimibe (reduces intestinal LDL absorption, proven to lower cardiovascular events)
2. Add PCSK9 inhibitors (e.g., evolocumab, alirocumab) if LDL goal still not reached - these monoclonal antibodies upregulate hepatic LDL receptors and have demonstrated reduction in MACE and major adverse lower extremity events

3. Blood Pressure Control

• Primary goal: reduce MACE
• ACE inhibitors are preferred - in the HOPE trial, ramipril reduced MI, stroke, and cardiovascular death by 25% vs. placebo in PAD patients
• Angiotensin receptor blockers (ARBs) are an alternative - In ONTARGET, telmisartan showed similar efficacy to ramipril with less angioedema
• Target BP: SBP < 140 mmHg, DBP < 90 mmHg (lower targets increasingly supported by cardiology guidelines)
• Importantly: beta-blockers are NOT contraindicated in PAD and may be used for concurrent cardiac indications

4. Glycemic Control (Diabetic Patients)

• DM significantly accelerates PAD progression; severity of disease correlates with chronic glucose exposure
• HbA1c target: <7% recommended by Global Vascular Guidelines for CLTI; <8% suggested by IWGDF to avoid hypoglycemia - individualize based on patient factors
• SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin): reduce cardiovascular mortality, heart failure, renal complications, MACE, and amputation
• GLP-1 receptor agonists (e.g., semaglutide, liraglutide): similar cardiovascular and renal benefits
• Tight glycemic control reduces microvascular complications short-term and macrovascular complications when sustained over decades

5. Symptom Management - Intermittent Claudication

Cilostazol

• Cilostazol 100 mg twice daily is a Class I recommendation (ACC/AHA) for intermittent claudication
• Mechanism: reversible PDE-IIIa inhibitor - causes vasodilation and inhibits platelet aggregation (increases cAMP in platelets and vascular smooth muscle)
• Based on a Cochrane review of 16 RCTs: significantly improves pain-free and maximum walking distance
• Key contraindication: Congestive heart failure of any severity (class effect of PDE3 inhibitors)
• Common side effects: headache, palpitations, diarrhea, dizziness (main reasons for noncompliance)
• Should NOT substitute for aspirin/clopidogrel in ACS patients with concurrent PAD

Pentoxifylline

• No longer recommended - removed from guidelines due to lack of demonstrated benefit

6. Smoking Cessation

• Assess smoking status at every visit
• Pharmacologic options (used alone or in combination):
  • Varenicline (most effective)
  • Bupropion
  • Nicotine replacement therapy (patches, gum, lozenges)
• Intensive smoking cessation intervention (behavioral + pharmacologic) resulted in 21.3% vs. 6.8% success at 6 months compared with minimal intervention

7. Supervised Exercise Therapy

• A Cochrane review of 32 RCTs (1,835 IC patients): exercise improved both pain-free and maximum walking distance vs. placebo/usual care
• A meta-analysis of 25 RCTs: supervised treadmill exercise improved walking performance by ~180 m vs. no exercise
• Since 2017, CMS covers up to 36 sessions over 12 weeks for PAD patients with walking impairment
• Protocol: Minimum 45-60 minutes, 3 times/week for 12 weeks; intensity sufficient to elicit claudication
• Home-based walking is a reasonable alternative for those without access to supervised programs

Summary Table

Peripheral Arterial Disease - Medical Management

1. Antithrombotic Therapy

Single Antiplatelet Therapy (SAPT) - First Line for All Symptomatic PAD

• Asymptomatic PAD: SAPT reasonable if reduced ABI + low bleeding risk, given high prevalence of subclinical CAD
• USPSTF 2022 guidance against aspirin for primary prevention in the general population does not override clinical judgment in established PAD

Dual Antiplatelet Therapy (DAPT)

• Aspirin + clopidogrel: NOT superior to aspirin alone in PAD (CHARISMA trial) and increases bleeding
• Exception: Aspirin + ticagrelor in PAD patients with prior MI reduces MACE and MALE (PEGASUS-TIMI 54)
• Commonly used post-peripheral intervention, though RCT data are limited

Low-Dose Anticoagulation (Vascular Dose Strategy)

• Rivaroxaban 2.5 mg BID + aspirin (COMPASS trial):
  • In 6,391 PAD patients: reduced MACE (5.1% vs. 6.9%, p=0.005) and MALE (HR 0.57)
• Rivaroxaban 2.5 mg BID + aspirin (VOYAGER-PAD trial):
  • In 6,564 post-revascularization patients: reduced composite of ALI, major amputation, MI, stroke, CV death (HR 0.85, p=0.009)
• Major bleeding increased, but fatal/critical organ bleeding was not significantly different
• Recommended in patients without elevated bleeding risk; full-dose anticoagulation is NOT routinely recommended

Vorapaxar

• PAR-1 thrombin receptor antagonist; approved for PAD patients to reduce thrombotic CV events
• Contraindicated in prior intracranial hemorrhage

2. Lipid-Lowering Therapy

• Statins reduce mortality, MACE, MALE, and improve walking symptoms
• Pleiotropic effects: improved endothelial function, plaque stabilization, reduced platelet aggregation
• VA study (155,647 patients): high-intensity statin at PAD diagnosis significantly reduced limb loss and mortality

3. Blood Pressure Control

• Target: SBP < 140 mmHg, DBP < 90 mmHg (lower targets increasingly supported)
• ACE inhibitors are preferred:
  • Ramipril: 25% reduction in MI, stroke, and CV death vs. placebo (HOPE trial, PAD subgroup)
• ARBs are an equivalent alternative:
  • Telmisartan showed similar efficacy to ramipril with less angioedema (ONTARGET)
• Beta-blockers are NOT contraindicated in PAD

4. Glycemic Control (Diabetic Patients)

• Individualize based on age, duration of DM, comorbidities, hypoglycemia risk
• SGLT2 inhibitors (empagliflozin, dapagliflozin): reduce CV mortality, heart failure, renal events, MACE, and amputation
• GLP-1 receptor agonists (semaglutide, liraglutide): reduce CV mortality and MACE

5. Symptom Management - Intermittent Claudication

Cilostazol (Class I Recommendation - ACC/AHA)

• Dose: 100 mg twice daily for a 3-month trial
• Mechanism: Reversible PDE-IIIa inhibitor → increases cAMP → vasodilation + antiplatelet effect
• Evidence: Cochrane review of 16 RCTs - significantly improves pain-free and maximum walking distance
• Contraindication: Heart failure of ANY severity (all PDE3 inhibitors)
• Side effects: Headache (most common), palpitations, diarrhea, dizziness
• Does NOT substitute for aspirin/clopidogrel in concurrent ACS

Pentoxifylline

• No longer recommended - removed from guidelines (lack of efficacy)

6. Smoking Cessation

• Associated with decreased mortality and improved amputation-free survival
• Assess at every visit; counsel + offer pharmacotherapy + refer to cessation program
• Intensive intervention: 21.3% vs. 6.8% success at 6 months vs. minimal intervention

7. Supervised Exercise Therapy

• Most effective non-interventional treatment for claudication symptoms
• Cochrane review (32 RCTs, 1,835 patients): improved pain-free and maximum walking distance
• Meta-analysis (25 RCTs): supervised treadmill exercise improved walking by ~180 m vs. no exercise
• CMS-covered: up to 36 sessions over 12 weeks for PAD patients with walking impairment (since 2017)
• Protocol: 45-60 min, 3x/week, 12 weeks; intensity sufficient to elicit claudication symptoms
• Home-based walking: reasonable alternative if supervised therapy is inaccessible

8. Wound and Foot Care (CLTI Patients)

• Multidisciplinary approach: vascular surgeon, wound care specialists, podiatry, nutritionists
• Regular foot inspection; patient education on footwear and skin care
• Early referral for non-healing wounds

Quick Reference Summary

MACE Prevention:
  ├── SAPT: Aspirin 75-325 mg OR Clopidogrel 75 mg (preferred in smokers)
  ├── Consider: Rivaroxaban 2.5 mg BID + ASA (if low bleeding risk)
  ├── Statin: LDL goal <70 mg/dL (+ ezetimibe / PCSK9i if needed)
  └── ACE inhibitor / ARB for BP control

Limb Symptom Relief (IC):
  ├── Supervised Exercise (36 sessions / 12 wk) - most effective
  └── Cilostazol 100 mg BID (contraindicated in CHF)

Risk Factor Modification:
  ├── Smoking cessation (varenicline preferred)
  ├── Diabetes: SGLT2i or GLP-1 agonist (HbA1c <7-8%)
  └── BP target: <140/90 mmHg

• 2024 ACC/AHA PAD Guideline - PMID 38743805
• 2024 ESC Guidelines for PAD and Aortic Diseases - PMID 39210722
• 2025 SVS Focused Update - Intermittent Claudication - PMID 40316185

Transfusion Target Hb in Suspected APL (with Hb 6 g/dL)

Short Answer

APL Is a Transfusion Emergency - Not Just for Anemia

• DIC (consumptive coagulopathy from release of procoagulant granule contents)
• Hyperfibrinolysis (primary fibrinolysis driven by leukemic cells)
• Resulting in life-threatening hemorrhage - most commonly intracranial (65%) or pulmonary hemorrhage (32%)

Full Transfusion Targets in Suspected APL

For your patient with Hb 6 g/dL: Transfuse 2 units pRBCs to bring Hb to ≥ 8 g/dL, and simultaneously check and aggressively correct platelets, fibrinogen, and INR.

Why a More Liberal Hb Target is Used in APL

1. Active or impending hemorrhage - even without overt bleeding, these patients are in a coagulopathic state
2. NCCN guidelines for leukemia-related anemia allow 8-10 g/dL if symptomatic
3. Maintaining higher Hb provides a buffer against sudden blood loss from hemorrhagic complications
4. Anemia itself can worsen tissue hypoxia in the context of shock from hemorrhage

What Else Must Be Done Immediately (Even Before Diagnosis Confirmed)

1. Start ATRA immediately on clinical/morphological suspicion (45 mg/m²/day in 2 divided doses) - do NOT wait for genetic confirmation. ATRA reduces the severity of DIC
2. Stop all anticoagulants and antiplatelets
3. Avoid invasive procedures - prefer PICC over central line
4. Monitor CBC, PT, aPTT, fibrinogen, D-dimer q6-12 hours until coagulopathy resolves
5. Daily D-dimer throughout hospitalization
6. Baseline Echo + ECG (required before starting arsenic trioxide/ATO)
7. Correct electrolytes (Mg, K) if starting ATO

Key Principle

In APL, fibrinogen correction (cryoprecipitate) and platelet support are more urgently life-saving than the Hb alone. A patient with Hb 6 who has fibrinogen 80 mg/dL is at far greater risk from intracranial hemorrhage than from anemia. Both must be corrected, but fibrinogen has priority.

Hyperthyroidism - Treatment

Overview of Treatment Modalities

Treatment Decision Flowchart

• Graves' disease (GD) + age < 65: ATDs first; RAI or surgery if comorbidity exists
• Graves' disease (GD) + age > 65: RAI or surgery (definitive)
• Toxic adenoma or toxic multinodular goiter (TA-TMNG): RAI or surgery regardless of age
• Grade 1 subclinical hyperthyroidism + age > 65 with cardiovascular risk/AF: RAI

1. Antithyroid Drugs (Thioamides)

Methimazole vs. Propylthiouracil (PTU)

Dosing Regimen

• Initial: 10-20 mg every 12 h (or 20-40 mg single dose for mild-moderate disease)
• Maintenance (titration): 2.5-10 mg once daily
• Block-replace regimen: fixed high dose + add LT4 to prevent hypothyroidism

• Initial: 100-200 mg every 6-8 h
• Maintenance: 50-150 mg once daily

Monitoring

• Thyroid function tests (free T4 preferred over TSH initially) at 4-6 weeks
• Euthyroidism typically achieved in 6-8 weeks
• TSH may remain suppressed for months - use free T4 as primary monitor early
• Titration regimen preferred (lower doses; monitors spontaneous remission)

Duration and Remission

• Treat for 12-18 months for maximum remission rates
• Remission rates: 30-60% (titration regimen)
• Relapse risk is higher in: young patients, males, smokers, large goiters, high TRAb, severe hyperthyroidism
• If relapsed: prolonged low-dose therapy for up to 10 years or switch to definitive therapy

Adverse Effects

2. Radioactive Iodine (RAI / ¹³¹I)

• Preferred treatment for most patients >21 years (especially in North America)
• Dose range: 370-555 MBq (10-15 mCi), or 80-120 μCi/g thyroid weight corrected for uptake
• Effect takes 6-12 weeks to achieve euthyroidism/hypothyroidism
• A second dose can be given 6 months later if insufficient response
• Hypothyroidism occurs in ~80% of patients → require lifelong LT4 replacement

Pre-RAI preparation:

• Stop methimazole 2-3 days before RAI (not to interfere with iodine uptake)
• May restart methimazole 3-7 days after RAI (tapering over 4-6 weeks)
• PTU requires longer washout before RAI (prolonged radioprotective effect)
• Avoid iodine-containing foods/contrast to maximize ¹³¹I uptake
• In elderly or cardiac patients: pretreat with ATDs until euthyroid before RAI

Contraindications to RAI:

• Absolute: Pregnancy, breast-feeding
• Relative: Active moderate-to-severe Graves' ophthalmopathy (can worsen eye disease, especially in smokers)
  • If RAI given with ophthalmopathy: cover with prednisone 0.2-0.5 mg/kg/day, tapered over 6-12 weeks

After RAI:

• Avoid close prolonged contact with children/pregnant women for 5-7 days
• Annual thyroid function testing required (progressive hypothyroidism: ~10-20% year 1, then 5%/year)
• Patients can conceive safely 6 months after RAI

3. Surgery (Total or Near-Total Thyroidectomy)

Indications:

• Very large goiters / multinodular goiters with compressive symptoms
• Suspicion of thyroid malignancy
• Coexisting hyperparathyroidism
• RAI contraindicated (pregnancy, active severe ophthalmopathy)
• Patient preference (especially young patients)
• Relapse after ATDs who prefer surgery over RAI

Pre-operative preparation:

1. Antithyroid drugs until euthyroid (~6 weeks)
2. Potassium iodide (SSKI): 1-2 drops orally TID for 10-14 days before surgery
   • Purpose: reduces vascularity of the gland, lowers risk of thyrotoxic crisis
   • Alternative: Lugol's iodine 5 drops BID x 10-14 days

Complications:

• Bleeding, laryngeal edema
• Hypoparathyroidism (hypocalcemia)
• Recurrent laryngeal nerve damage (hoarseness)
• These are rare when performed by experienced surgeons
• ~80-90% will require lifelong LT4 replacement after near-total thyroidectomy

4. Adjunct Therapy - Beta Blockers

• Age ≥ 60 years
• Heart rate > 90 bpm
• Cardiovascular disease
• Thyrotoxic periodic paralysis

• Taper and withdraw as thyroid hormone levels normalize
• If beta blockers contraindicated (e.g., asthma): use diltiazem 90-120 mg TID-QID

Additional adjuncts:

• Cholestyramine (bile acid sequestrant): rapidly lowers T4 by increasing fecal excretion
• Barbiturates: accelerate T4 breakdown via hepatic enzyme induction
• Digoxin: may be needed for AF in thyrotoxicosis, but requires higher doses (increased clearance)
• Warfarin: requires lower doses when patient is thyrotoxic (enhanced catabolism of clotting factors)
• Anticoagulation: Consider in all patients with AF (CHA₂DS₂-VASc score); most revert to sinus rhythm after euthyroidism achieved

5. Iodide (Lugol's / SSKI)

• Mechanism: Inhibits iodination of tyrosines (Wolff-Chaikoff effect) + blocks hormone release from thyroglobulin
• Wolff-Chaikoff effect lasts only a few days (escape occurs)
• Uses:
  • Pre-operative preparation (reduces gland vascularity)
  • Thyroid storm
• NOT suitable for long-term therapy
• Adverse effects: sore mouth/throat, tongue swelling, metallic taste, mucosal ulcerations

6. Special Situations

Toxic Multinodular Goiter / Toxic Adenoma

• RAI is the preferred treatment
• Very large goiters: surgery (subtotal thyroidectomy)
• Pre-treat with methimazole before definitive therapy

Subclinical Hyperthyroidism

• Grade 1 (TSH 0.1-0.4 mU/L): Treatment NOT recommended in asymptomatic young/premenopausal women
• Grade 2 (TSH < 0.1 mU/L) or older patients with cardiac risk: Treat (RAI or ATDs)
• LT4 suppression therapy: only justified in high-risk thyroid cancer patients

Pregnancy

• RAI is absolutely contraindicated in pregnancy and breast-feeding
• Breast-feeding is safe with low doses of ATDs

7. Thyroid Storm (Thyrotoxic Crisis)

Quick Reference Summary

Graves' Disease:
  Young, mild disease → ATDs (methimazole x 12-18 months)
  Older / cardiac disease → RAI (definitive)
  Large goiter / malignancy suspicion → Surgery
  Pregnancy (T1) → PTU → switch to methimazole T2/T3
  
Toxic Nodular → RAI or Surgery

Symptom Control → Beta blocker (propranolol/atenolol)

Pre-surgery → ATD to euthyroid + SSKI x 10-14 days
Pre-RAI → Stop MMI 2-3 days before; restart 3-7 days after

Thyroid Storm → PTU + Iodide (1hr later) + Propranolol + Hydrocortisone

Hyperthyroidism

Definition

Causes and Classification

Primary Hyperthyroidism (↑T3/T4, ↓TSH, ↑Radioiodine uptake)

Thyrotoxicosis WITHOUT Hyperthyroidism (↓Radioiodine uptake)

Graves' Disease - Pathogenesis

• Thyroid-stimulating immunoglobulins (TSI) / TRAb - present in ~90% of patients - bind and continuously stimulate the TSH receptor, mimicking TSH → unregulated T3/T4 production
• TPO antibodies and thyroglobulin antibodies also present in up to 80% of cases
• Genetic associations: CTLA4, PTPN22, IL2RA polymorphisms; TSHR gene variants; HLA-B8/DR3 in Caucasians

1. Hyperthyroidism with diffuse goiter
2. Infiltrative ophthalmopathy (exophthalmos)
3. Infiltrative dermopathy (pretibial myxedema) - in minority

Clinical Features

General Symptoms and Signs (Any Cause of Thyrotoxicosis)

Apathetic thyrotoxicosis: Seen in the elderly - presents with fatigue, weight loss, and AF, with minimal hyperadrenergic features. Easy to miss.

Graves'-Specific Features

• Occurs in ~1/3 of Graves' patients clinically; detectable by CT/US in most
• Mechanism: Activated T cells release IFN-γ, TNF, IL-1 → fibroblast proliferation → glycosaminoglycan accumulation → retro-orbital tissue expansion → proptosis
• TSH-R expressed in orbital tissue; IGF-1R signaling on orbital fibroblasts also implicated
• Earliest symptoms: gritty eye sensation, excess tearing, eye discomfort
• Advanced: proptosis (>22 mm), diplopia, corneal ulceration, optic nerve compression → vision loss
• Occurs in 10% of patients WITHOUT hyperthyroidism (euthyroid ophthalmopathy)

• <5% of patients; almost always with moderate-to-severe ophthalmopathy
• Indurated, non-pitting purple/skin-colored lesions over anterior shin
• Contain large amounts of glycosaminoglycans (hyaluronic acid, chondroitin sulfate)

• Rare triad: digital clubbing, soft tissue swelling of hands/feet, periosteal reaction of distal metatarsals

Diagnosis

Step 1 - Biochemical Confirmation

TSH is the most sensitive biomarker - start here. A normal TSH effectively excludes thyrotoxicosis.

Step 2 - Diagnostic Algorithm

Step 3 - Distinguishing the Cause

Other Lab Abnormalities in Thyrotoxicosis

• ↑ Bilirubin, ↑ liver enzymes, ↑ ferritin
• Microcytic anemia, thrombocytopenia
• Mild hypercalcemia (~20%), hypercalciuria
• Elevated sex hormone-binding globulin

Cardiovascular Complications

• Atrial fibrillation: More common >50 years; up to 75% revert to sinus rhythm after achieving euthyroidism
• Heart failure: Especially with preexisting cardiac disease; high-output state progresses to failure
• Angina precipitation: High O₂ demand in setting of ischemic heart disease
• Hypokalemic periodic paralysis: Particularly in Asian males with thyrotoxicosis
• Thromboembolic events: Embolic stroke from AF; hyperthyroidism is a hypercoagulable state

Note: Warfarin requirement is decreased in thyrotoxicosis (increased clotting factor catabolism). Digoxin requires higher doses (increased clearance).

Thyroid Storm (Thyrotoxic Crisis)

• Thermoregulatory: High fever (often >38.5°C)
• Cardiovascular: Extreme tachycardia, AF, heart failure, hypotension
• CNS: Agitation, confusion, seizures, coma
• GI/hepatic: Nausea, vomiting, jaundice

1. PTU 600 mg load then 200-250 mg q4h (preferred over MMI in storm - also blocks T4→T3)
2. Wait 1 hour, then give Lugol's iodine/SSKI (prevents iodide being used as substrate)
3. Propranolol 60-80 mg PO q4h or IV esmolol (controls adrenergic symptoms)
4. Hydrocortisone 100 mg IV q8h (blocks T4→T3; treats relative adrenal insufficiency)
5. Paracetamol for fever - NOT aspirin (aspirin displaces T4 from binding proteins)
6. ICU admission + treat underlying precipitant

Treatment Summary (see previous detailed response)

Subclinical Hyperthyroidism

• TSH ↓, normal free T4 and T3
• Grade 1: TSH 0.1-0.4 mU/L; usually from autonomous nodules; treat only if symptomatic or >65 years with cardiac risk
• Grade 2: TSH <0.1 mU/L; treat (atrial fibrillation risk, osteoporosis risk)
• Risk of AF is 3-fold higher, risk of fracture is 2-fold higher in overt subclinical hyperthyroidism

Thyroid Function Test Interpretation

The Results

Interpretation

Primary Diagnosis: Overt Primary Hyperthyroidism

• TSH < 0.0083 mIU/L is profoundly suppressed - well below the lower normal limit of 0.45 mIU/L. Modern sensitive TSH assays can detect down to ≤0.004-0.01 mIU/L; this value indicates near-total TSH suppression from excessive negative feedback by circulating thyroid hormones
• Free T4 of 22.9 pmol/L is above the upper reference limit (~12-22 pmol/L), confirming true overt hyperthyroidism - not just subclinical disease
• Total T4 of 198.46 nmol/L (~15.4 µg/dL) also exceeds the adult upper limit of ~154 nmol/L (12.5 µg/dL)

Important Note: "Normal" fT4?

• Even if fT4 22.9 is within your lab's range, a TSH of <0.0083 with ANY elevation in thyroid hormones is still diagnostic of overt hyperthyroidism
• The TSH is the most sensitive indicator - a profoundly suppressed TSH in the context of elevated total T4 confirms the diagnosis regardless of how fT4 is classified

Why is Total T4 Elevated More Than Free T4?

1. Actual hyperthyroidism (both total and free T4 rise together - as here)
2. Elevated TBG from: estrogens (OCP, pregnancy, HRT, tamoxifen), acute hepatitis, familial TBG excess

Differential Diagnosis of This Pattern

Next Steps

1. Check free T3 - in 2-5% of thyrotoxicosis, only T3 is elevated (T3 toxicosis); important to get baseline
2. TRAb / TSI - confirm/exclude Graves' disease
3. Anti-TPO antibodies - supports autoimmune etiology
4. Thyroid ultrasound with Doppler - goiter size, nodules, vascularity ("thyroid inferno" in Graves')
5. Radionuclide scan (¹²³I or ⁹⁹ᵐTc) if needed - differentiates high-uptake (Graves', toxic nodule) from low-uptake (thyroiditis, factitia) causes
6. Clinical assessment - symptoms (palpitations, weight loss, tremor, heat intolerance), goiter, ophthalmopathy, HR, BP, tremor

One Important Caveat

Summary

TSH < 0.0083 + fT4 22.9 pmol/L + Total T4 198.46 nmol/L = Overt primary hyperthyroidism. This patient requires clinical evaluation to determine the underlying cause (most likely Graves' disease), followed by initiation of antithyroid therapy (methimazole or propylthiouracil), beta-blocker for symptomatic relief, and endocrinology referral.

Vancomycin: High Trough After Stopping - When to Recheck

The Core Principle: Half-Lives

Vancomycin Half-Life by Renal Function

When to Recheck After a High Trough

Context 1: Treatment is CONTINUING - dose held due to high trough

Context 2: Treatment is STOPPED/COMPLETED - high trough found at end of therapy

Wait 1-2 half-lives (until the level is estimated to be in/near the target range), then recheck to confirm clearance before considering any future redosing or assessing nephrotoxicity.

• Normal renal function (CrCl >60): Recheck in 24-48 hours
• Mild-moderate impairment (CrCl 30-60): Recheck in 48-72 hours
• Severe impairment (CrCl <30) or AKI: Recheck in 72-96 hours or longer
• ESRD/anuria: Level may take days to weeks to clear; recheck every 48-72h

The Calculation Approach (Pharmacokinetic Method)

C₂ = C₁ × e^(-ke × t)

Where:
C₁ = current high trough
C₂ = target acceptable level (e.g., 15 mg/L)
ke = elimination rate constant (0.693 / t½)
t = time to wait (solve for this)

• ke = 0.693/12 = 0.058/h
• t = ln(28/15) / 0.058 = 0.624 / 0.058 ≈ ~11 hours → recheck in ~12 hours

Key Points to Remember

1. Renal function drives everything - always check current CrCl/creatinine before estimating when to recheck
2. AKI worsens accumulation - if creatinine is rising, the drug is clearing slower than expected; recheck sooner rather than later and monitor closely
3. "Improving" renal function after AKI can mean the drug clears faster - consider rechecking earlier
4. Do NOT restart vancomycin until the level is confirmed to be in the safe range (typically < 15-20 mg/L depending on indication)
5. Nephrotoxicity risk: Supratherapeutic troughs > 20 mg/L are associated with vancomycin-induced nephrotoxicity; monitor daily creatinine
6. AUC-guided dosing (now preferred over trough-only per 2020 ASHP/IDSA/SIDP guidelines): AUC target 400-600 mg·h/L; if only trough monitoring is available, target trough is 10-20 mg/L depending on indication

Summary Table

Practical rule of thumb: Wait ~1-2 half-lives (based on renal function) before rechecking. In normal renal function, recheck in 24 hours. In significant renal impairment, recheck in 48-72 hours.

Blood Transfusion in Dengue Hemorrhagic Shock

The Direct Answer

Packed Red Blood Cells (pRBCs): 5-10 mL/kg over 1-2 hours Fresh Whole Blood: 10-20 mL/kg over 1-2 hours

When is Blood Transfusion Indicated?

1st → IV Crystalloid resuscitation (isotonic saline/Ringer's lactate)
2nd → Colloid (albumin, Dextran-40) if refractory to crystalloids
3rd → Blood transfusion - ONLY when:
       • Hematocrit FALLS (< 45% or drops significantly)
       • Clinically significant/overt hemorrhage is confirmed
       • Shock persists despite crystalloids + colloids

Transfusion Rates - Guidelines Summary

Packed Red Blood Cells (pRBCs)

Fresh Whole Blood

• Whole blood: 1 unit over 1-2 hours
• pRBCs: 1 unit over 1 hour

Why This Specific Rate? (The Rationale)

• Too slow → patient remains in shock, organ damage progresses
• Too fast → fluid overload once capillary leak stops (reabsorption phase) → pulmonary edema, respiratory failure

What Products to Give (and NOT Give)

Note on platelets: Although not routinely recommended, some experts consider platelet transfusion for persistent severe life-threatening bleeding in patients who are PPI (proton pump inhibitor) responders with refractory thrombocytopenia.

Monitoring After Transfusion

• Vital signs (BP, HR, pulse pressure)
• Hematocrit - should stabilize or rise
• Urine output (target >1 mL/kg/hr)
• Signs of fluid overload (respiratory rate, SpO₂)

Full Shock Management Algorithm

Dengue with Shock
        ↓
IV Crystalloid: 20 mL/kg over 15-30 min
        ↓
Improved? → Step down fluids: 10→7→5→3→1.5 mL/kg/hr
        ↓
Not improved → Repeat crystalloid 20 mL/kg x2
        ↓
Not improved → Check ABCS:
   A = Acidosis   B = Bleeding (check Hct)
   C = Calcium    S = Blood Sugar
        ↓
Hct FALLING (<45%) = Overt bleeding
→ pRBCs 5-10 mL/kg OR Whole blood 10 mL/kg over 1-2 hrs
        ↓
Still not improved → Colloid (Dextran-40, albumin) 10 mL/kg
→ Inotropes if refractory
→ ICU / higher care

Ketamine Infusion in ICU - Intubated/Mechanically Ventilated Patients

Dose by Indication (Key Distinction)

1. Analgesia / Analgosedation (Sub-Dissociative Dose)

Note: SCCM PADIS 2018 uses µg/kg/min: 1-2 µg/kg/min = 0.06-0.12 mg/kg/hr

2. Sedation (Dissociative/Anesthetic Dose)

Full Dosing Reference Table

Why Ketamine is Attractive in the ICU

Monitoring Parameters

Contraindications in ICU

Note on ICP: The historical contraindication in traumatic brain injury/raised ICP has been largely revised. Recent evidence suggests ketamine does not significantly increase ICP in mechanically ventilated patients already receiving appropriate sedation/analgesia.

Practical ICU Protocol Summary

Intubated ICU Patient - Ketamine Infusion

Goal: Analgesia adjunct (opioid-sparing)
  → Start: 0.1-0.2 mg/kg/hr
  → Range: 0.05-0.5 mg/kg/hr
  → Titrate: pain score (CPOT/BPS <3)

Goal: Primary sedation / analgosedation
  → Loading dose: 0.5-1 mg/kg IV over 5-15 min
  → Start infusion: 0.5-1 mg/kg/hr
  → Titrate: RASS target (usually -2 to -3)
  → Max: 4-5 mg/kg/hr

Monitor:
  • HR, BP q1h
  • RASS q2-4h
  • Secretions
  • LFTs if >5 days

N-Acetylcysteine (NAC) in Acute Liver Failure - Role and Dosing

Mechanism of Action

Role in ALF - By Etiology

1. Acetaminophen (Paracetamol)-Induced ALF - ESTABLISHED, LEVEL I

• NAC is the definitive antidote - nearly 100% hepatoprotective if given within 8 hours of ingestion
• Within 12 hours: still prevents most liver injury
• Beyond 24 hours: reduces mortality and complications even in established liver failure
• Start immediately on suspicion - do NOT wait for acetaminophen levels
• Indication: any patient above the treatment line on the Rumack-Matthew nomogram
• Continue beyond 21-hour protocol if liver injury is progressing (elevated/rising INR, ALT, encephalopathy)

2. Non-Acetaminophen ALF (NA-ALF) - EVIDENCE-BASED, RECOMMENDED

• 173 patients with NA-ALF (DILI, viral, autoimmune, indeterminate)
• NAC vs. placebo (72-hour infusion protocol)
• Transplant-free survival: 40% (NAC) vs. 27% (placebo), p=0.043
• Benefit restricted to Grade I-II hepatic encephalopathy (West Haven)
• No benefit in Grade III-IV encephalopathy

Guideline Positions on NA-ALF:

Dosing Protocols

Standard 21-Hour IV Protocol (Acetaminophen ALF - Primary)

Max weight cap: Dose calculated on actual body weight up to 100 kg maximum

Children < 20 kg: Use reduced dextrose volumes (3 mL/kg, 7 mL/kg, 14 mL/kg for bags 1, 2, 3 respectively)

Extended Protocol - When to Continue Beyond 21 Hours

• Acetaminophen still detectable in serum
• INR > 1.5
• ALT/AST > 50 IU/L (or not declining toward 50% of peak)
• Ongoing encephalopathy
• Liver injury still progressing

72-Hour Protocol for Non-Acetaminophen ALF (Lee et al. Regimen)

72-Hour Oral Protocol (Alternative - Only if IV not feasible)

• Dilute to 5% solution; mix with soft drink/juice for palatability
• Re-administer any vomited dose
• IV route is strongly preferred in ALF (vomiting, encephalopathy, GI bleeding make oral unreliable)

Emerging: 2-Bag Simplified Protocol (Growing Use in US)

• Fewer medication errors (27% → 11% error rate in studies)
• Similar efficacy and adverse event profile
• Not yet universally adopted but gaining acceptance

Criteria to STOP NAC (After Standard Protocol)

1. Serum acetaminophen level is undetectable
2. INR ≤ 1.5
3. ALT/AST < 50 IU/L OR declining toward 50% of peak
4. No encephalopathy
5. Clinical improvement

Adverse Effects of IV NAC

Anaphylactoid reactions are not true IgE-mediated anaphylaxis - NAC can be restarted at slower rate after reaction resolves. They are most common with the rapid loading dose (15-minute bag 1 infusion increased reactions vs. 1-hour infusion).

Summary Quick Reference

ACETAMINOPHEN ALF:
  → IV NAC: 150 mg/kg/1h → 50 mg/kg/4h → 100 mg/kg/16h
  → Total: 300 mg/kg over 21 hours
  → Extend if INR >1.5, ALT not normalizing, ongoing encephalopathy
  → Start immediately - do NOT wait for levels

NON-ACETAMINOPHEN ALF (DILI, viral, autoimmune, indeterminate):
  → Same IV protocol for 72 hours
  → Loading: 150 mg/kg/1h → 12.5 mg/kg/hr × 4h → 6.25 mg/kg/hr × 67h
  → Benefits ONLY in Grade I-II hepatic encephalopathy
  → EASL recommends for ALL causes; AASLD recommends for DILI + possible APAP

KEY POINT: IV route always preferred in ALF
           Max weight for dosing = 100 kg
           Extend beyond standard protocol if liver injury ongoing